Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial

L. Wu,Z. Wu,Z. Xiao,Z. Ma,J. Weng,Y. Chen,Y. Cao,P. Cao,M. Xiao,H. Zhang,H. Duan,Q. Wang, J. Li,Y. Xu,X. Pu,K. Li

JOURNAL OF THORACIC ONCOLOGY（2021）

Cited 1|Views23
Key words
Anlotinib, EGFR wild-type NSCLC, Second-line therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined